The Cyclosporine-A Treatment does not have Harmful Effect on the Linear Growth of Pediatric Patients with Steroid-dependent and Steroid-resistant Nephrotic Syndrome.
10.3339/jkspn.2016.20.2.45
- Author:
Sang Soo LEE
1
;
Ji Hoon KIM
;
Chung Ho KIM
;
Byoung Soo CHO
;
Deog Yoon KIM
;
Il Ki HONG
;
Jin Soon SUH
Author Information
1. Department of Pediatrics, Bucheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea. rebekahjs@hanmail.net
- Publication Type:Original Article
- Keywords:
Cyclosporine A;
Glucocorticoid;
Children;
Nephrotic syndrome;
Growth
- MeSH:
Child;
Cyclosporine;
Diagnosis;
Follow-Up Studies;
Humans;
Nephrotic Syndrome*;
Retrospective Studies
- From:Childhood Kidney Diseases
2016;20(2):45-49
- CountryRepublic of Korea
- Language:English
-
Abstract:
PURPOSE: This study was performed to evaluate the effects of cyclosporine-A (CsA) on linear growth in pediatric patients with steroid-dependent (SDNS) or resistant nephrotic syndrome (SRNS). METHODS: Thirty-five pediatric patients with SDNS or SRNS undergoing glucocorticoid (GC) and/or CsA treatment were retrospectively reviewed. Seventeen patients were treated with GC alone and 18 were treated with GC and CsA. The cumulative doses of GC and CsA were quantified (mg/kg/day). Linear growth during the follow-up period was defined as the difference in Z-score between the initial and final height according to the follow-up period (Δ height Z score/year). The associations between linear growth and clinical parameters were analyzed. RESULTS: The linear growth of patients in the two groups was not significantly different (P=0.262). The Δ height Z score/year did not show a significant correlation with the cumulative doses of CsA, but was negatively correlated with the cumulative dose of GC and positively correlated with the Z score for height at the time of diagnosis. CONCLUSION: In children with SDNS or SRNS undergoing GC therapy, added CsA treatment may not have harmful effects on linear growth.
